These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29141791)

  • 21. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
    Lampl C; You X; Limmroth V
    Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM
    Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
    Fox RJ; Salter AR; Tyry T; Sun J; You X; Laforet G; Campagnolo D
    Int J MS Care; 2013; 15(4):194-201. PubMed ID: 24453783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):230-6. PubMed ID: 25887773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    McDonell J; Costello K; Laurson-Doube J; Rijke N; Giovannoni G; Banwell B; Baneke P
    Mult Scler; 2020 Feb; 26(2):153-158. PubMed ID: 31944872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Tolley K; Hutchinson M; You X; Wang P; Sperling B; Taneja A; Siddiqui MK; Kinter E
    PLoS One; 2015; 10(6):e0127960. PubMed ID: 26039748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
    Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.
    Khan O; Zabad R; Caon C; Zvartau-Hind M; Tselis A; Lisak R
    CNS Drugs; 2002; 16(8):563-78. PubMed ID: 12096936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
    Rudick RA
    J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS.
    Francis GS
    J Neurol; 2004 Sep; 251 Suppl 5():v42-v49. PubMed ID: 15549355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.